



Kevin Ali
NewCo CEO



Kevin Ali has been announced as the CEO of NewCo, a global biopharmaceutical leader in women's health formed when it was spun off from Merck and NewCo. With more than 3 decades of pharmaceutical and commercial experience, he brings extensive knowledge of the industry's customers, therapeutic areas, and subsidiary operations to lead the creation and expansion of NewCo.

Kevin has spent the last 30 years with Merck in a number of leadership roles, most recently heading its enterprise portfolio strategy initiative, reporting to Kenneth C. Frazier, Chairman and CEO of Merck. In this role, Kevin has been responsible for evaluating the company's transformation of the Human Health portfolio, including greater focus on strategic priorities.

Prior to this, Kevin was President, MSD International, where he was responsible for the management of all commercial markets outside the US. These markets account for 96 percent of the world's population, and over half of Merck's pharmaceutical and vaccines revenues. In addition, Kevin had global responsibility for the company's Diversified Brands business, a portfolio of mature products that plays a critical role in serving the needs of customers and patients around the world. Under his leadership, MSD International was a significant driver of the company's growth and financial results. Before leading MSD International, Kevin was President of the Emerging Markets region and reshaped the performance of many markets into sustained growth and strength. In this role, Kevin championed a strategic shift towards the company's innovative products, the introduction of important commercial and development partnerships, and a number of transformational agreements with key customers.

Kevin was Senior Vice President and General Manager of the Bone, Respiratory, Immunology, and Dermatology (BRID) franchise; Senior Vice President and Managing Director of MSD Germany; and Managing Director of MSD Turkey and served in several other senior leadership roles in the company. Kevin began his Merck career in 1988, as a Hospital and Specialty Sales Representative in California. Kevin holds an MBA from Santa Clara University and a Bachelor of Arts from the University of California, Berkeley.

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through Merck's prescription medicines, vaccines, biologic therapies and animal health products, the company works with customers and operates in more than 140 countries to deliver innovative health solutions. Merck also demonstrates our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world — including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases, including HIV and Ebola. For more information, visit www.merck.com and connect with Merck on [Twitter](#), [Facebook](#), [YouTube](#) and [LinkedIn](#).